<DOC>
	<DOCNO>NCT01330017</DOCNO>
	<brief_summary>The trial evaluate nasal congestion symptom relief approve 10 mg phenylephrine ( PE ) dose high 20 mg , 30 mg , 40 mg PE dose compare placebo participant history seasonal allergic rhinitis , use loratadine background medication .</brief_summary>
	<brief_title>Effects Phenylephrine Nasal Congestion Participants With Seasonal Allergic Rhinitis ( P08156 AM2 ) ( Completed )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>Inclusion criterion : Female participant reproductive potential must negative pregnancy test agree use acceptable method birth control throughout study . Participant willing stop use current decongestant allergy medication trial . Participant document selfreported history seasonal allergy . Participant document positive skin test spring pollen allergen . Participant nasal congestion least moderate severity . Participant mean seat ( 5 minute rest ) systolic/diastolic blood pressure â‰¤138/88 mmHg . Participant clinically acceptable physical exam 12lead electrocardiogram ( ECG ) . Participant without clinically significant disease . Participant must agree take monoamine oxidase inhibitor ( MAOI ) 14 day trial participation 14 day end trial . Participant must sign informed consent form Exclusion criterion : Participants must significant medical condition contraindication use phenylephrine HCl loratadine , thyroid disease , uncontrolled diabetes mellitus , coronary heart disease , ischemic heart disease , elevate intraocular pressure , prostatic hypertrophy . Participants history presence hypertension . Participants start allergen immunotherapy within month precede enrollment start allergen immunotherapy anticipate immunotherapy dose change trial . Xolair ( omalizumab ) may use within 4 year prior trial participation . Participants know allergy intolerance phenylephrine HCl , decongestant , loratadine , desloratadine , antihistamine . Participants persistent asthma , rhinitis medicamentosa , acute chronic sinusitis , history significant sinusitis within one month enrollment . Participant history intermittent asthma may consider enrollment provide asthma symptom time enrollment use short act beta2agonist less twice weekly . Participants use systemic ( oral , rectal , injectable ) , topical , nasal corticosteroid last 30 day ( 1 % topical hydrocortisone permit ) . Participants use leukotriene receptor antagonist maintenance treatment asthma . Participant history illness , opinion study investigator , might confound result study pose additional risk participant participation study . Participant history immunological disease malignancy within past 5 year , exception nonmelanoma skin cancer . Participant positive drug screen ( participant prescribe medication result positive drug screen result may still enrol discretion investigator ) . Participant major surgery participate another investigational study within 4 week prior Screening Visit . Participants take herbal supplement trial conduct .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Seasonal allergy</keyword>
</DOC>